Details of the Drug

General Information of Drug (ID: DMPDQ8T)

Drug Name

AB-103

Synonyms

Superantigen toxin antagonist (iv/infusion, septic shock/toxic shock), Atox Bio/Hebrew University of Jerusalem

Indication

Disease Entry	ICD 11	Status	REF
Necrotizing soft tissue infection	1B71	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

281.25

Logarithm of the Partition Coefficient (xlogp)

0.8

Rotatable Bond Count (rotbonds)

6

Hydrogen Bond Donor Count (hbonddonor)

1

Hydrogen Bond Acceptor Count (hbondacc)

5

Chemical Identifiers

Formula: C12H16N3O3P
IUPAC Name: benzyl N-[bis(aziridin-1-yl)phosphoryl]carbamate
Canonical SMILES: C1CN1P(=O)(NC(=O)OCC2=CC=CC=C2)N3CC3
InChI: InChI=1S/C12H16N3O3P/c16-12(18-10-11-4-2-1-3-5-11)13-19(17,14-6-7-14)15-8-9-15/h1-5H,6-10H2,(H,13,16,17)
InChIKey: VFIUCBTYGKMLCM-UHFFFAOYSA-N

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cell-specific surface glycoprotein CD28 (CD28)	TTQ13FT	CD28_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT02469857) Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)